{"entity":{"id":"nct06167317","kind":"trial","name":"Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT06167317 as recruiting, last updated 2026-08-13. Enrolment is 278 planned participants, an estimate. Interventions: GS-0201, Sacituzumab Govitecan. Primary measures include The Number of Participants with Dose Limiting Toxicities (DLTs) During Dose Escalation; The Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs). No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06167317","url":"https://clinicaltrials.gov/study/NCT06167317"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp","trop2"],"drugs":["gs-0201","sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06167317","phase":"1","setting":"A Phase 1 Study to Evaluate the Safety and Tolerability of GS-0201 as Monotherapy and in Combination in Adults With Advanced Solid Tumors","sponsor":"Gilead Sciences","started":"2024-01-09","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06167317/","neighbours":{"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"gs-0201","kind":"drug","name":"GS-0201","route":"/drugs/gs-0201/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}]}}